scispace - formally typeset
Open AccessJournal ArticleDOI

Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia.

Reads0
Chats0
TLDR
Throughout 6 months, eszopiclone improved all of the components of insomnia as defined by DSM-IV, including patient ratings of daytime function, which is compelling evidence that long-term pharmacologic treatment of insomnia is efficacious.
Abstract
STUDY OBJECTIVES To determine the long-term efficacy of eszopiclone in patients with chronic insomnia. DESIGN Randomized, double-blind, multicenter, placebo-controlled. SETTING Out-patient, with monthly visits. PATIENTS Aged 21 to 69 years meeting DSM IV criteria for primary insomnia and reporting less than 6.5 hours of sleep per night, and/or a sleep latency of more than 30 minutes each night for at least 1 month before screening. INTERVENTIONS Eszopiclone 3 mg (n = 593) or placebo (n = 195), nightly for 6 months MEASUREMENTS AND RESULTS Efficacy was evaluated weekly using an interactive voice-response system. Endpoints included sleep latency; total sleep time; number of awakenings; wake time after sleep onset; quality of sleep; and next-day ratings of ability to function, daytime alertness, and sense of physical well-being. At the first week and each month for the study duration, eszopiclone produced significant and sustained improvements in sleep latency, wake time after sleep onset, number of awakenings, number of nights awakened per week, total sleep time, and quality of sleep compared with placebo (P < or = 0.003). Monthly ratings of next-day function, alertness, and sense of physical well-being were also significantly better with the use of eszopiclone than with placebo (P < or = 0.002). There was no evidence of tolerance, and the most common adverse events were unpleasant taste and headache. CONCLUSIONS Throughout 6 months, eszopiclone improved all of the components of insomnia as defined by DSM-IV, including patient ratings of daytime function. This placebo-controlled study of eszopiclone provides compelling evidence that long-term pharmacologic treatment of insomnia is efficacious.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Clinical Guideline for the Evaluation and Management of Chronic Insomnia in Adults

TL;DR: This clinical guideline is to provide clinicians with a practical framework for the assessment and disease management of chronic adult insomnia, using existing evidence-based insomnia practice parameters where available, and consensus-based recommendations to bridge areas where such parameters do not exist.
Journal ArticleDOI

Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians

TL;DR: This guideline is based on a systematic review of randomized, controlled trials published in English from 2004 through September 2015 and recommends that all adult patients receive cognitive behavioral therapy for insomnia (CBT-I) as the initial treatment for chronic insomnia disorder.
Journal ArticleDOI

Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline

TL;DR: This guideline is designed to establish clinical practice recommendations for the pharmacologic treatment of chronic insomnia in adults, when such treatment is clinically indicated, and includes drugs that are FDA-approved for the treatment of insomnia, as well as several drugs commonly used to treat insomnia without an FDA indication.
References
More filters
Journal ArticleDOI

Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial.

TL;DR: Behavioral and pharmacological approaches are effective for the short-term management of insomnia in late life; sleep improvements are better sustained over time with behavioral treatment.
Journal ArticleDOI

Chronic Insomnia Is Associated with Nyctohemeral Activation of the Hypothalamic-Pituitary-Adrenal Axis: Clinical Implications

TL;DR: It is concluded that insomnia is associated with an overall increase of ACTH and cortisol secretion, which, however, retains a normal circadian pattern, consistent with a disorder of central nervous system hyperarousal rather than one of sleep loss, which is usually associated with no change or decrease in cortisol secretion or a circadian disturbance.
Journal ArticleDOI

Benzodiazepines and Zolpidem for Chronic Insomnia: A Meta-analysis of Treatment Efficacy

TL;DR: Benzodiazepines and zolpidem produced reliable improvements in commonly measured parameters of sleep in patients with chronic insomnia, and presented challenges for developing evidence-based guidelines for the use of hypnotics in the management of chronic insomnia.
Journal ArticleDOI

Epidemiological study on insomnia in the general population

TL;DR: A low family income, being a woman, being over 65 years of age, being retired and being separated, divorced or widowed are significantly associated with the presence of UQS, and the consumption of sleep-enhancing medication and medication to reduce anxiety is important.
Related Papers (5)